This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Palanisamy, N. Articles by Arnold, A. Search for Related Content PubMed PubMed Citation Articles by Palanisamy, N. Articles by Arnold, A.

Novel Chromosomal Abnormalities Identified by Comparative Genomic Hybridization in Parathyroid Adenomas¹

Cell Biology Program (N.P., P.H.R., R.S.K.C.), Memorial Sloan-Kettering Cancer Center, New York, New York 10021; Laboratory of Endocrine Oncology (Y.I., H.T., A.A.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114; and Center for Molecular Medicine (Y.I., A.A.), University of Connecticut School of Medicine, Farmington, Connecticut 06030-1316

Address all correspondence and requests for reprints to: Dr. Andrew Arnold, Center for Molecular Medicine and Division of Endocrinology and Metabolism, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, Connecticut 06030-1316.

The molecular basis of parathyroid adenomatosis includes defects in the cyclin D1/PRAD1 and MEN1 genes but is, in large part, unknown. To identify new locations of parathyroid oncogenes or tumor suppressor genes, and to further establish the importance of DNA losses described by molecular allelotyping, we performed comparative genomic hybridization (CGH) on a panel of 53 typical sporadic (nonfamilial) parathyroid adenomas. CGH is a new molecular cytogenetic technique in which the entire tumor genome is screened for chromosomal gains and/or losses. Two abnormalities, not previously described, were found recurrently: gain of chromosome 16p (6 of 53 tumors, or 11%) and gain of chromosome 19p (5 of 53, or 9%). Losses were found frequently on 11p (14 of 53, or 26%), as well as 11q (18 of 53, or 34%). Recurrent losses were also seen on chromosomes 1p, 1q, 6q, 9p, 9q, 13q, and 15q, with frequencies ranging from 8–19%. Twenty-four of the 53 adenomas were also extensively analyzed with polymorphic microsatellite markers for allelic losses, either in this study (11 cases) or previously (13 cases). Molecular allelotyping results were highly concordant with CGH results in these tumors (concordance level of 97.5% for all informative markers/chromosome arms examined).

In conclusion, CGH has identified the first two known chromosomal gain defects in parathyroid adenomas, suggesting the existence of direct-acting parathyroid oncogenes on chromosomes 16 and 19. CGH has confirmed the locations of putative parathyroid tumor suppressor genes, also defined by molecular allelotyping, on chromosomes 1p, 6q, 9p, 11q, 13q, and 15q. Finally, CGH has provided new evidence favoring the possibility that distinct parathyroid tumor suppressors exist on 1p and 1q, and has raised the possibility of a parathyroid tumor suppressor gene on 11p, distinct from the MEN1 gene on 11q. CGH can identify recurrent genetic abnormalities in hyperparathyroidism, especially chromosomal gains, that other methods do not detect.

This article has been cited by other articles:

				A. Y.M. Au, K. McDonald, A. Gill, M. Sywak, T. Diamond, A. D. Conigrave, and R. J. Clifton-Bligh PTH Mutation with Primary Hyperparathyroidism and Undetectable Intact PTH N. Engl. J. Med., September 11, 2008; 359(11): 1184 - 1186. [Full Text] [PDF]

				E. H. Samander and A. Arnold Mutational Analysis of the Vitamin D Receptor Does Not Support Its Candidacy as a Tumor Suppressor Gene in Parathyroid Adenomas J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 5019 - 5021. [Abstract] [Full Text] [PDF]

				T. Kawata, Y. Imanishi, K. Kobayashi, T. Kenko, M. Wada, E. Ishimura, T. Miki, N. Nagano, M. Inaba, A. Arnold, et al. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism Eur. J. Endocrinol., October 1, 2005; 153(4): 587 - 594. [Abstract] [Full Text] [PDF]

				L. Forsberg, E. Bjorck, J. Hashemi, J. Zedenius, A. Hoog, L.-O. Farnebo, M. Reimers, and C. Larsson Distinction in gene expression profiles demonstrated in parathyroid adenomas by high-density oligoarray technology Eur. J. Endocrinol., March 1, 2005; 152(3): 459 - 470. [Abstract] [Full Text] [PDF]

				J Warner, M Epstein, A Sweet, D Singh, J Burgess, S Stranks, P Hill, D Perry-Keene, D Learoyd, B Robinson, et al. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications J. Med. Genet., March 1, 2004; 41(3): 155 - 160. [Abstract] [Full Text] [PDF]

				H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass Angiogenesis in Endocrine Tumors Endocr. Rev., October 1, 2003; 24(5): 600 - 632. [Abstract] [Full Text] [PDF]

				S. M. Mallya, J. J. Gallagher, and A. Arnold Analysis of Microsatellite Instability in Sporadic Parathyroid Adenomas J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1248 - 1251. [Abstract] [Full Text] [PDF]

				J. Gogusev, I. Murakami, M. Doussau, L. Telvi, A. Stojkoski, P. Lesavre, and D. Droz Molecular Cytogenetic Aberrations in Autosomal Dominant Polycystic Kidney Disease Tissue J. Am. Soc. Nephrol., February 1, 2003; 14(2): 359 - 366. [Abstract] [Full Text] [PDF]

				T. Dwight, A. E. Nelson, G. Theodosopoulos, A. L. Richardson, D. L. Learoyd, J. Philips, L. Delbridge, J. Zedenius, B. T. Teh, C. Larsson, et al. Independent Genetic Events Associated with the Development of Multiple Parathyroid Tumors in Patients with Primary Hyperparathyroidism Am. J. Pathol., October 1, 2002; 161(4): 1299 - 1306. [Abstract] [Full Text] [PDF]

				T. M. Shattuck, J. Costa, M. Bernstein, R. T. Jensen, D. C. Chung, and A. Arnold Mutational Analysis of Smad3, a Candidate Tumor Suppressor Implicated in TGF-{beta} and Menin Pathways, in Parathyroid Adenomas and Enteropancreatic Endocrine Tumors J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3911 - 3914. [Abstract] [Full Text] [PDF]

				E. Szabo, T. Carling, O. Hessman, and J. Rastad Loss of Heterozygosity in Parathyroid Glands of Familial Hypercalcemia with Hypercalciuria and Point Mutation in Calcium Receptor J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3961 - 3965. [Abstract] [Full Text] [PDF]

				Y. Imanishi, H. Tahara, N. Palanisamy, S. Spitalny, I. B. Salusky, W. Goodman, M. L. Brandi, T. B. Drueke, E. Sarfati, P. Urena, et al. Clonal Chromosomal Defects in the Molecular Pathogenesis of Refractory Hyperparathyroidism of Uremia J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1490 - 1498. [Abstract] [Full Text] [PDF]

				K. Sato, T. Obara, K. Yamazaki, M. Kanbe, K. Nakajima, A. Yamada, T. Yanagisawa, Y. Kato, T. Nishikawa, and K. Takano Somatic Mutations of the MEN1 Gene and Microsatellite Instability in a Case of Tertiary Hyperparathyroidism Occurring during High Phosphate Therapy for Acquired, Hypophosphatemic Osteomalacia J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5564 - 5571. [Abstract] [Full Text] [PDF]

				S. Hemmer, V.-M. Wasenius, C. Haglund, Y. Zhu, S. Knuutila, K. Franssila, and H. Joensuu Deletion of 11q23 and Cyclin D1 Overexpression Are Frequent Aberrations in Parathyroid Adenomas Am. J. Pathol., April 1, 2001; 158(4): 1355 - 1362. [Abstract] [Full Text] [PDF]

				H. Tahara, Y. Imanishi, T. Yamada, Y. Tsujimoto, T. Tabata, T. Inoue, M. Inaba, H. Morii, and Y. Nishizawa Rare Somatic Inactivation of the Multiple Endocrine Neoplasia Type 1 Gene in Secondary Hyperparathyroidism of Uremia J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4113 - 4117. [Abstract] [Full Text]

				S. Kytola, F. Farnebo, T. Obara, J. Isola, L. Grimelius, L.-O. Farnebo, K. Sandelin, and C. Larsson Patterns of Chromosomal Imbalances in Parathyroid Carcinomas Am. J. Pathol., August 1, 2000; 157(2): 579 - 586. [Abstract] [Full Text] [PDF]

				S. B. Brown, T. T. Brierley, N. Palanisamy, I. B. Salusky, W. Goodman, M. L. Brandi, T. B. Drüeke, E. Sarfati, P. Ureña, R. S. K. Chaganti, et al. Vitamin D Receptor as a Candidate Tumor-Suppressor Gene in Severe Hyperparathyroidism of Uremia J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 868 - 872. [Abstract] [Full Text]

				F. Farnebo, S. Kytola, B. T. Teh, T. Dwight, F. K. Wong, A. Hoog, M. Elvius, W. S. Wassif, N. W. Thompson, L.-O. Farnebo, et al. Alternative Genetic Pathways in Parathyroid Tumorigenesis J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3775 - 3780. [Abstract] [Full Text] [PDF]

				S. J. Marx CLINICAL REVIEW 109: Contrasting Paradigms for Hereditary Hyperfunction of Endocrine Cells J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3001 - 3009. [Full Text]